Natera logo

NateraNASDAQ: NTRA

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 July 2015

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$15.45 B
-6%vs. 3y high
95%vs. sector
-vs. 3y high
-vs. sector
-6%vs. 3y high
97%vs. sector
-43%vs. 3y high
77%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:49:31 GMT
$124.88+$0.72(+0.58%)

Dividend

No data over the past 3 years
$413.35 M$361.45 M
$413.35 M-$37.46 M

Analysts recommendations

Institutional Ownership

NTRA Latest News

All You Need to Know About Natera (NTRA) Rating Upgrade to Strong Buy
zacks.com23 October 2024 Sentiment: POSITIVE

Natera (NTRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
businesswire.com14 September 2024 Sentiment: POSITIVE

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is one of the largest and most comprehensive prospective studies of circulating tumor DNA (ctDNA) testing in resectable colorectal cancer (CRC). This latest analysis, which will also.

Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
businesswire.com08 September 2024 Sentiment: POSITIVE

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain. Natera and its collaborators will present a total of nine abstracts, including five poster presentations from the GALAXY observational arm of.

Natera: Focus On Signatera And H1 2024 Results
seekingalpha.com14 August 2024 Sentiment: POSITIVE

Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed tests year-over-year, positioning it as the company's fastest-growing product. The liquid biopsy market is projected to grow at an 11% CAGR, with significant expansion in North America, supporting the long-term growth potential of Signatera.

Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
zacks.com08 August 2024 Sentiment: POSITIVE

The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Natera (NTRA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.97 per share a year ago.

Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
businesswire.com03 July 2024 Sentiment: POSITIVE

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA. Below is the list of poster presentations that will be shared at the.

Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
businesswire.com17 June 2024 Sentiment: POSITIVE

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera's ability to detect rejection in heart transplant patients. Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by.

Final Trades: Amazon, Natera and KKR & Co.
youtube.com10 June 2024 Sentiment: POSITIVE

The Investment Committee gives you their top stocks to watch for the second half.

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
businesswire.com30 May 2024 Sentiment: POSITIVE

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024. Natera and its collaborators will present 18 abstracts highlighting new Prospera data across heart, lung, kidney, and multi-organ transplantation. This includes an oral presentation highlightin.

  • 1(current)

What type of business is Natera?

Natera, Inc. is a diagnostic company that provides services in the field of reproductive health and genetic disease diagnostics. The company was founded in 2004 and is located in San Carlos, California. The company's main product is Panorama, a non-invasive prenatal test (NIPT) that detects fetal chromosomal abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, and triploidy. It also detects pathologies that often lead to intellectual disabilities, severe organ anomalies, and miscarriage. Panorama can also determine the sex of the fetus in a singleton pregnancy, as well as each fetus in a twin pregnancy. Panorama is also the only commercially available NIPT that can determine whether a set of twins is identical, monozygotic, dizygotic, or trizygotic.

What sector is Natera in?

Natera is in the Healthcare sector

What industry is Natera in?

Natera is in the Diagnostics & Research industry

What country is Natera from?

Natera is headquartered in United States

When did Natera go public?

Natera initial public offering (IPO) was on 01 July 2015

What is Natera website?

https://www.natera.com

Is Natera in the S&P 500?

No, Natera is not included in the S&P 500 index

Is Natera in the NASDAQ 100?

No, Natera is not included in the NASDAQ 100 index

Is Natera in the Dow Jones?

No, Natera is not included in the Dow Jones index

When was Natera the previous earnings report?

No data

When does Natera earnings report?

The next expected earnings date for Natera is 08 November 2024